Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.

Huiyue LiJennifer K PlichtaKan LiYizi JinSamantha M ThomasFei MaLi TangQingyi WeiYou-Wen HeQichen ChenYuanyuan GuoYueping LiuJian ZhangSheng Luo

Published in: Breast cancer research and treatment (2023)

In both early-stage HR-positive and TNBC patients, HER2-low status was associated with lower pCR rates. HER2-zero status might be considered an adverse prognostic factor for OS in patients not achieving pCR.

Keyphrases

prognostic factors
early stage
neoadjuvant chemotherapy
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
sentinel lymph node
squamous cell carcinoma
radiation therapy
patient reported outcomes
young adults
adverse drug